{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:34:20Z","timestamp":1768880060914,"version":"3.49.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>BK polyomavirus (BKPyV) nephropathy is a significant complication of kidney transplantation associated with high levels of BKPyV replication in plasma and poor graft survival. It is currently treated by reducing immunosuppression to restore the immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We analyzed circulating T cells from 28 kidney transplant recipients with detectable levels of BKPyV DNA in the blood (BKPyV DNAemia). Immunosuppression was significantly reduced in all these patients. We evaluated BKPyV-specific T-cell functionality and phenotype and assessed graft outcomes prospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      BKPyV DNAemia was rapidly controlled in 13 patients (controllers [C] group), whereas viral replication was sustained in the other 15, who were considered not to have responded to reduced immunosuppression (noncontroller [NC] group). The induction and maintenance therapies used were similar in the C and NC groups. The slope of renal function decline tended to be worse in the NC group than in the C group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.055). BKPyV-specific T-cell functions (T-cell proliferation and cytokine secretion) were weaker in the NC group than in the C group. This functional impairment was associated with an overexpression of several inhibitory receptors (programmed cell death protein 1 [PD1], T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains, or T-cell immunoglobulin and mucin-containing protein 3 [TIM3]), highlighting an exhausted-like phenotype of BKPyV-specific CD4 and CD8 T cells in the NC group. T-cell inhibition was not overcome by a single blocking antibody against inhibitory receptors, whereas a combination of anti-PD1 and anti-TIM3 antibodies significantly restored BKPyV-specific CD8 T-cell functions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Sustained BKPyV DNAemia was associated with an exhausted phenotype of BKPyV-specific T cells despite immunosuppression reduction in kidney transplant recipients. We show that anti-BKPyV-specific CD8 functions can be restored ex vivo by blocking the PD1 and TIM3 pathways, paving the way for new treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005448","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:31Z","timestamp":1750118431000},"page":"e254-e265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["BKPyV-specific T-cell Exhaustion in Kidney Transplant Recipients: Targeting Inhibitory Receptors Improves Their Functionality"],"prefix":"10.1097","volume":"110","author":[{"given":"Karen","family":"Bargiel","sequence":"first","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Scriabine","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Herr","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ghislaine","family":"de Go\u00ebr de Herve","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houria","family":"Hendel-Chavez","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Taoufik","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slim","family":"Fourati","sequence":"additional","affiliation":[{"name":"Department of Virology, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Creteil, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Dekeyser","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."},{"name":"Department of Nephrology, Centre Hospitalier R\u00e9gional Universitaire d\u2019Orl\u00e9ans, Orl\u00e9ans, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Durrbach","sequence":"additional","affiliation":[{"name":"INSERM UMR1186, Immunologie int\u00e9grative des tumeurs et immunoth\u00e9rapie des cancers, Gustave Roussy Institute, Villejuif, France."},{"name":"Facult\u00e9 de Medecin Le Kremlin Bicetre, Paris-Saclay University, Paris, France."},{"name":"Department of Nephrology and Transplantation, Henri Mondor Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Creteil, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"R1-20260119","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.transproceed.2004.09.019","article-title":"Changes in quality of life after renal transplantation.","volume":"37","author":"Overbeck","year":"2005","journal-title":"Transplant Proc"},{"key":"R2-20260119","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20260119","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajt.12110","article-title":"BK polyomavirus in solid organ transplantation.","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"R4-20260119","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1469-0691.12538","article-title":"European perspective on human polyomavirus infection, replication and disease in solid organ transplantation.","volume":"20","author":"Hirsch","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R5-20260119","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"key":"R6-20260119","doi-asserted-by":"crossref","first-page":"704","DOI":"10.12659\/AOT.910483","article-title":"Risk factors of acute rejection in patients with BK nephropathy after reduction of immunosuppression.","volume":"23","author":"Baek","year":"2018","journal-title":"Ann Transplant"},{"key":"R7-20260119","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors.","volume":"199","author":"Egli","year":"2009","journal-title":"J Infect Dis"},{"key":"R8-20260119","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(03)00770-9","article-title":"Polyomavirus BK.","volume":"3","author":"Hirsch","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"R9-20260119","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QCO.0000000000000602","article-title":"BK polyomavirus-specific antibody and T-cell responses in kidney transplantation: update.","volume":"32","author":"Kaur","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"R10-20260119","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation.","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"R11-20260119","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1523-1755.2005.00602.x","article-title":"BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients.","volume":"68","author":"Vasudev","year":"2005","journal-title":"Kidney Int"},{"key":"R12-20260119","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/01.ASN.0000023435.07320.81","article-title":"Clinical course of polyoma virus nephropathy in 67 renal transplant patients.","volume":"13","author":"Ramos","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R13-20260119","first-page":"53","article-title":"BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program.","volume":"143","author":"Ramos","year":"2002","journal-title":"Clin Transpl"},{"key":"R14-20260119","first-page":"58","article-title":"Long-term follow-up of active treatment versus minimization of immunosuppressive agents in patients with BK virus-associated nephropathy after kidney transplant.","volume":"14","author":"Halim","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"R15-20260119","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.ekir.2024.04.070","article-title":"Allogeneic CD4 T cells sustain effective BK polyomavirus-specific CD8 T cell response in kidney transplant recipients.","volume":"9","author":"Dekeyser","year":"2024","journal-title":"Kid Int Rep"},{"key":"R16-20260119","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/ajt.13252","article-title":"The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication.","volume":"15","author":"Schachtner","year":"2015","journal-title":"Am J Transplant"},{"key":"R17-20260119","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fimmu.2015.00307","article-title":"Polyomavirus-specific cellular immunity: from BK-virus-specific cellular immunity to BK-virus-associated nephropathy?","volume":"6","author":"Dekeyser","year":"2015","journal-title":"Front Immunol"},{"key":"R18-20260119","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fimmu.2019.00767","article-title":"BKV clearance time correlates with exhaustion state and T-cell receptor repertoire shape of BKV-specific T-cells in renal transplant patients.","volume":"10","author":"Stervbo","year":"2019","journal-title":"Front Immunol"},{"key":"R19-20260119","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"key":"R20-20260119","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1128\/JVI.75.12.5550-5558.2001","article-title":"Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.","volume":"75","author":"Gruener","year":"2001","journal-title":"J Virol"},{"key":"R21-20260119","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"R22-20260119","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections.","volume":"479-480","author":"Kahan","year":"2015","journal-title":"Virology"},{"key":"R23-20260119","doi-asserted-by":"crossref","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signaling"},{"key":"R24-20260119","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"R25-20260119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta.","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"R26-20260119","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease.","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"R27-20260119","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma.","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"R28-20260119","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"R29-20260119","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Resp Med"},{"key":"R30-20260119","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study.","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"R31-20260119","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"R32-20260119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"R33-20260119","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"R34-20260119","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1681\/ASN.2017050477","article-title":"The Banff Working Group Classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations.","volume":"29","author":"Nickeleit","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R35-20260119","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.humpath.2005.08.009","article-title":"Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods.","volume":"36","author":"Drachenberg","year":"2005","journal-title":"Hum Pathol"},{"key":"R36-20260119","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/ajt.14282","article-title":"BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the Swiss Transplant Cohort Study.","volume":"17","author":"Leboeuf","year":"2017","journal-title":"Am J Transplant"},{"key":"R37-20260119","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/ajt.12689","article-title":"BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication.","volume":"14","author":"Schmidt","year":"2014","journal-title":"Am J Transplant"},{"key":"R38-20260119","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/j.1600-6143.2011.03693.x","article-title":"BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy.","volume":"11","author":"Schachtner","year":"2011","journal-title":"Am J Transplant"},{"key":"R39-20260119","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/TP.0000000000001314","article-title":"Increased frequency of BK virus-specific polyfunctional CD8+ T cells predict successful control of BK viremia after kidney transplantation.","volume":"101","author":"Schaenman","year":"2016","journal-title":"Transplantation"},{"key":"R40-20260119","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2018.10.002","article-title":"Risk factors for BK virus viremia and nephropathy after kidney transplantation: a systematic review.","volume":"109","author":"Demey","year":"2018","journal-title":"J Clin Virol"},{"key":"R41-20260119","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/TP.0000000000000890","article-title":"Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis.","volume":"100","author":"Thangaraju","year":"2016","journal-title":"Transplantation"},{"key":"R42-20260119","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer.","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"R43-20260119","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","article-title":"Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity.","volume":"22","author":"Collier","year":"2021","journal-title":"Nat Immunol"},{"key":"R44-20260119","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"Cell exhaustion.","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"R45-20260119","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.4049\/jimmunol.176.4.2238","article-title":"Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF.","volume":"176","author":"Nakae","year":"2006","journal-title":"J Immunol"},{"key":"R46-20260119","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R47-20260119","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"R48-20260119","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1128\/JVI.00873-11","article-title":"Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses.","volume":"86","author":"Lachmann","year":"2012","journal-title":"J Virol"},{"key":"R49-20260119","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade.","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R50-20260119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"R51-20260119","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"R52-20260119","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"R53-20260119","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"R54-20260119","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection.","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"R55-20260119","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review.","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"key":"R56-20260119","doi-asserted-by":"crossref","first-page":"e13399","DOI":"10.1111\/tid.13399","article-title":"T-cell adoptive immunotherapy for BK nephropathy in renal transplantation.","volume":"22","author":"Jahan","year":"2020","journal-title":"Transplant Infect Dis"},{"key":"R57-20260119","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/infdis\/jiaa546","article-title":"BK Polyomavirus-Specific CD8 T-cell expansion in vitro using 27mer peptide antigens for developing adoptive T-cell transfer and vaccination.","volume":"223","author":"Wilhelm","year":"2021","journal-title":"J Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:00:38Z","timestamp":1768834838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005448","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}